Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
19 06 2020
Historique:
received: 24 03 2020
revised: 21 04 2020
accepted: 07 05 2020
pubmed: 19 5 2020
medline: 28 4 2021
entrez: 19 5 2020
Statut: ppublish

Résumé

Among the high risk groups, patients with multiple myeloma (MM) have one of the highest incidence of invasive pneumococcal disease, mainly pneumonias. Recent changes in MM treatment have now led to an increase of survival, while the infection-related mortality remains high. The question of efficacy of pneumococcal vaccination in patients receiving novel target agents has not been clinically investigated before. We have introduced the 3-dose vaccination regimen by 13-valent pneumococcal conjugate (PCV13) vaccine between the treatment courses with novel target agents (bortezomib, lenalidomide, ixazomib) with a minimum of 1 month interval. The incidence of pneumonias during the one-year observation period was taken as a primary outcome in this registered clinical trial. From 2017 to 2020, we have prospectively included 18 adult patients who were vaccinated by PCV13 along with 18 patients of a control matched group. No adverse effects of vaccination were registered in the study. We have observed an independent effect of PCV13 vaccination on the incidence of pneumonias. The absolute risk reduction of pneumonias in patients received PCV13 vaccination was 33.3%. Number needed to treat for PCV13 vaccination in multiple myeloma patients receiving novel agents was 3.0; (95% CI 1.61-22.1; p = 0.0571). Therefore, we have shown the clinical effectiveness of PCV13 vaccination schedule based on 3 doses given with a minimum 1 month interval between the courses of novel agents in multiple myeloma patients, despite the expected decrease in immunological response to vaccination during target and immunotherapy. ClinicalTrials.gov Identifier: NCT03619252.

Identifiants

pubmed: 32418789
pii: S0264-410X(20)30643-5
doi: 10.1016/j.vaccine.2020.05.024
pii:
doi:

Substances chimiques

Antibodies, Bacterial 0
Pneumococcal Vaccines 0
Vaccines, Conjugate 0

Banques de données

ClinicalTrials.gov
['NCT03619252']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4713-4716

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Igor Stoma (I)

Department of Infectious Diseases, Belarusian State Medical University, Minsk, Belarus; Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Belarus. Electronic address: igor.stoma@gmail.com.

Igor Karpov (I)

Department of Infectious Diseases, Belarusian State Medical University, Minsk, Belarus.

Igor Iskrov (I)

Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Belarus.

Irina Lendina (I)

Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Belarus.

Anatoly Uss (A)

Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Belarus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH